# US 9,435,808 B2 · Myeloperoxidase, a risk indicator for cardiovascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,435,808 B2
- Document ID: US9435808B2
- Status: Granted
- Kind: B2
- Application number: 14/984,072
- Filed: 2015-12-30
- Published: 2016-04-21
- Granted: 2016-09-06
- Earliest claimed: 2001-01-02
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Stanley L. Hazen; Renliang Zhang
- Web page: https://patentgrep.com/patent/US9435808B2

## CPC

- G01N 33/573: for enzymes or isoenzymes
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 1/28: aliphatic
- C12Q 1/28: involving peroxidase
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16Z 99/00: Subject matter not provided for in other main groups of this subclass
- C12Y 111/01007: Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
- G01N 2333/908: acting on hydrogen peroxide as acceptor (1.11)
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16Z: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.

## Claims

### Claim 1

A method for administering a lipid lowering agent to a human patient based on elevated levels of myeloperoxidase (MPO) comprising:
(a) performing an immunological assay comprising contacting a serum or plasma sample with an anti-MPO antibody to determine the MPO level in the serum or plasma sample;
(b) selecting a human patient who has an elevated MPO level compared to the level of MPO in the general population or apparently healthy control subjects; and
(c) administering a lipid lowering agent to the human patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein said bodily sample is plasma.

### Claim 3 (depends on 1)

The method of claim 1, wherein bodily sample is serum.

### Claim 4 (depends on 1)

The method of claim 1, further comprising: providing printed material characterizing said human patient's risk of cardiovascular disease based upon the outcome of said assay.